Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPECT Trial: Partial Immune-boost TACE in Unresectable HCC Under Systemic Treatment
NCT07168668Phase 2Not yet recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Feb 2027
- Primary completion
- Aug 2029
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, tremelimumab, atezolizumab, bevacizumab and doxorubicin in hepatocellular carcinoma (HCC), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Progression-Free Survival at 12 months. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
durvalumabtremelimumabatezolizumabbevacizumabdoxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07168668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168668.